William Camu

List of Publications by Year
in descending order

154	11,602	36271	30058
papers	citations	51 h-index	103 g-index

191	191	191	13427
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nature Genetics, 2008, 40, 572-574.	9.4	1,371
2	Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nature Genetics, 2013, 45, 1353-1360.	9.4	1,213
3	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet, The, 2018, 391, 1263-1273.	6.3	684
4	Neurotrophins promote motor neuron survival and are present in embryonic limb bud. Nature, 1993, 363, 266-270.	13.7	605
5	TAR DNA-binding protein 43 (TDP-43) regulates stress granule dynamics via differential regulation of G3BP and TIA-1. Human Molecular Genetics, 2011, 20, 1400-1410.	1.4	323
6	TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration. Annals of Neurology, 2009, 65, 470-473.	2.8	278
7	SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis: genotype-phenotype correlations. Journal of Medical Genetics, 2010, 47, 554-560.	1.5	266
8	Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurology, The, 2018, 17, 405-415.	4.9	238
9	Neuromyelitis optica in France. Neurology, 2010, 74, 736-742.	1.5	196
10	A Major Determinant for Binding and Aminoacylation of tRNAAla in Cytoplasmic Alanyl-tRNA Synthetase Is Mutated in Dominant Axonal Charcot-Marie-Tooth Disease. American Journal of Human Genetics, 2010, 86, 77-82.	2.6	194
11	A Frameshift Deletion in Peripherin Gene Associated with Amyotrophic Lateral Sclerosis. Journal of Biological Chemistry, 2004, 279, 45951-45956.	1.6	163
12	Contribution of TARDBP mutations to sporadic amyotrophic lateral sclerosis. Journal of Medical Genetics, 2008, 46, 112-114.	1.5	162
13	Phenotype difference between ALS patients with expanded repeats inC9ORF72and patients with mutations in other ALS-related genes. Journal of Medical Genetics, 2012, 49, 258-263.	1.5	157
14	Purification of embryonic rat motoneurons by panning on a monoclonal antibody to the low-affinity NGF receptor. Journal of Neuroscience Methods, 1992, 44, 59-70.	1.3	153
15	Causes of death amongst French patients with amyotrophic lateral sclerosis: a prospective study. European Journal of Neurology, 2008, 15, 1245-1251.	1.7	135
16	High metabolic level in patients with familial amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 113-117.	2.3	135
17	Switching From Natalizumab to Fingolimod in Multiple Sclerosis. JAMA Neurology, 2014, 71, 436.	4.5	133
18	Recessive amyotrophic lateral sclerosis families with the D90A SOD1 mutation share a common founder: evidence for a linked protective factor. Human Molecular Genetics, 1998, 7, 2045-2050.	1.4	132

#	Article	IF	Citations
19	A Novel Locus for Familial Amyotrophic Lateral Sclerosis, on Chromosome 18q. American Journal of Human Genetics, 2002, 70, 251-256.	2.6	131
20	Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1251-1261.	1.4	131
21	Mutations in FUS cause FALS and SALS in French and French Canadian populations. Neurology, 2009, 73, 1176-1179.	1.5	129
22	Deleterious mutations in the essential mRNA metabolism factor, hGle1, in amyotrophic lateral sclerosis. Human Molecular Genetics, 2015, 24, 1363-1373.	1.4	122
23	A blinded international study on the reliability of genetic testing for GGGGCC-repeat expansions inC9orf72reveals marked differences in results among 14 laboratories. Journal of Medical Genetics, 2014, 51, 419-424.	1.5	118
24	Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Annals of Neurology, 2019, 85, 470-481.	2.8	118
25	Dietary BMAA Exposure in an Amyotrophic Lateral Sclerosis Cluster from Southern France. PLoS ONE, 2013, 8, e83406.	1.1	116
26	Abnormal SMN1 gene copy number is a susceptibility factor for amyotrophic lateral sclerosis. Annals of Neurology, 2002, 51, 243-246.	2.8	111
27	Three Families With Amyotrophic Lateral Sclerosis and Frontotemporal Dementia With Evidence of Linkage to Chromosome 9p. Archives of Neurology, 2007, 64, 240.	4.9	111
28	Long-term follow-up of neuromyelitis optica with a pediatric onset. Neurology, 2010, 75, 1084-1088.	1.5	101
29	C9ORF72 Repeat Expansions in the Frontotemporal Dementias Spectrum of Diseases: A Flow-chart for Genetic Testing. Journal of Alzheimer's Disease, 2013, 34, 485-499.	1.2	93
30	Chromosome 9p-linked families with frontotemporal dementia associated with motor neuron disease. Neurology, 2009, 72, 1669-1676.	1.5	90
31	Apolipoprotein E genotyping in sporadic amyotrophic lateral sclerosis: evidence for a major influence on the clinical presentation and prognosis. Journal of the Neurological Sciences, 1996, 139, 34-37.	0.3	84
32	Compound heterozygous D90A and D96N SOD1 mutations in a recessive amyotrophic lateral sclerosis family. Annals of Neurology, 2001, 49, 267-271.	2.8	80
33	SMN1 gene, but not SMN2, is a risk factor for sporadic ALS. Neurology, 2006, 67, 1147-1150.	1.5	80
34	Association of Long ATXN2 CAG Repeat Sizes With Increased Risk of Amyotrophic Lateral Sclerosis. Archives of Neurology, 2011, 68, 739-42.	4.9	80
35	Vitamin D confers protection to motoneurons and is a prognostic factor of amyotrophic lateral sclerosis. Neurobiology of Aging, 2014, 35, 1198-1205.	1.5	78
36	Association between centromeric deletions of theSMN gene and sporadic adult-onset lower motor neuron disease. Annals of Neurology, 1998, 43, 640-644.	2.8	75

#	Article	IF	Citations
37	Identification of Six Novel SOD1 Gene Mutations in Familial Amyotrophic Lateral Sclerosis. Canadian Journal of Neurological Sciences, 1998, 25, 192-196.	0.3	75
38	Investigating the contribution of VAPB/ALS8 loss of function in amyotrophic lateral sclerosis. Human Molecular Genetics, 2013, 22, 2350-2360.	1.4	75
39	FUS mutations in frontotemporal lobar degeneration with amyotrophic lateral sclerosis. Journal of Alzheimer's Disease, 2010, 22, 765-9.	1.2	75
40	Genetics of familial ALS and consequences for diagnosis. Journal of the Neurological Sciences, 1999, 165, S21-S26.	0.3	74
41	Phenotype and genotype analysis in amyotrophic lateral sclerosis with TARDBP gene mutations. Neurology, 2012, 78, 1519-1526.	1.5	72
42	Fasting plasma and CSF amino acid levels in amyotrophic lateral sclerosis: a subtype analysis. Acta Neurologica Scandinavica, 1993, 88, 51-55.	1.0	71
43	Cholecalciferol in relapsing-remitting MS: A randomized clinical trial (CHOLINE). Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, .	3.1	70
44	Screening of OPTN in French familial amyotrophic lateral sclerosis. Neurobiology of Aging, 2011, 32, 557.e11-557.e13.	1.5	68
45	Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance. Journal of Autoimmunity, 2017, 79, 84-90.	3.0	67
46	Systems Medicine Approaches for the Definition of Complex Phenotypes in Chronic Diseases and Ageing. From Concept to Implementation and Policies. Current Pharmaceutical Design, 2014, 20, 5928-5944.	0.9	63
47	Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2017, 16, 208-216.	4.9	62
48	An Update on Vitamin D and Disease Activity in Multiple Sclerosis. CNS Drugs, 2019, 33, 1187-1199.	2.7	59
49	Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis. European Journal of Neurology, 2020, 27, 251-257.	1.7	58
50	Four familial ALS pedigrees discordant for two SOD1 mutations: are all SOD1 mutations pathogenic?. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 572-577.	0.9	57
51	Amyotrophic lateral sclerosis: A hormonal condition?. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 585-588.	2.3	57
52	Lethal multiple sclerosis relapse after natalizumab withdrawal. Neurology, 2012, 79, 2214-2216.	1.5	56
53	Mutations of the ANG Gene in French Patients With Sporadic Amyotrophic Lateral Sclerosis. Archives of Neurology, 2008, 65, 1333.	4.9	52
54	Resequencing of 29 Candidate Genes in Patients With Familial and Sporadic Amyotrophic Lateral Sclerosis. Archives of Neurology, 2011, 68, 587-93.	4.9	52

#	Article	IF	Citations
55	Association of paraoxonase gene cluster polymorphisms with ALS in France, Quebec, and Sweden. Neurology, 2008, 71, 514-520.	1.5	51
56	Chromogranin B P413L variant as risk factor and modifier of disease onset for amyotrophic lateral sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 21777-21782.	3.3	49
57	Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial. Lancet Neurology, The, 2018, 17, 689-698.	4.9	48
58	Bullous Pemphigoid and Amyotrophic Lateral Sclerosis. Archives of Dermatology, 2000, 136, 521-4.	1.7	47
59	Vitamin <scp>D</scp> is associated with degree of disability in patients with fully ambulatory relapsingâ€“remitting multiple sclerosis. European Journal of Neurology, 2015, 22, 564-569.	1.7	47
60	Motor neuron disease after electric injury. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 71, 265-267.	0.9	46
61	Association of Variants in the SPTLC1 Gene With Juvenile Amyotrophic Lateral Sclerosis. JAMA Neurology, 2021, 78, 1236.	4.5	46
62	Analysis of OPTN as a causative gene for amyotrophic lateral sclerosis. Neurobiology of Aging, 2011, 32, 555.e13-555.e14.	1.5	43
63	Regulation of Brain Cholesterol: What Role Do Liver X Receptors Play in Neurodegenerative Diseases?. International Journal of Molecular Sciences, 2019, 20, 3858.	1.8	42
64	Acute hepatitis after riluzole administration. Journal of Hepatology, 1999, 30, 527-530.	1.8	41
65	Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial. EBioMedicine, 2020, 59, 102844.	2.7	41
66	A Clustering of Conjugal Amyotrophic Lateral Sclerosis in Southeastern France. Archives of Neurology, 2003, 60, 553.	4.9	40
67	Mutation Screening of the ALS2 Gene in Sporadic and Familial Amyotrophic Lateral Sclerosis. Archives of Neurology, 2003, 60, 1768.	4.9	40
68	UBQLN2 mutations are rare in French and Frenchâ€“Canadian amyotrophic lateral sclerosis. Neurobiology of Aging, 2012, 33, 2230.e1-2230.e5.	1.5	40
69	Neuroimmunity dynamics and the development of therapeutic strategies for amyotrophic lateral sclerosis. Frontiers in Cellular Neuroscience, 2013, 7, 214.	1.8	39
70	Coexistence of dominant and recessive familial amyotrophic lateral sclerosis with the D90A Cu,Zn superoxide dismutase mutation within the same country. European Journal of Neurology, 2000, 7, 207-211.	1.7	37
71	A prospective observational postâ€marketing study of natalizumabâ€treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The <scp>BIONAT</scp> cohort. European Journal of Neurology, 2014, 21, 40-48.	1.7	37
72	Hydrogen peroxide-induced motoneuron apoptosis is prevented by poly ADP ribosyl synthetase inhibitors. NeuroReport, 1998, 9, 1835-1838.	0.6	34

#	Article	IF	Citations
73	Mutations in UBQLN2 are rare in French amyotrophic lateral sclerosis. Neurobiology of Aging, 2012, 33, 839.e1-839.e3.	1.5	34
74	Association between divalent metal transport 1 encoding gene (SLC11A2) and disease duration in amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 2011, 303, 124-127.	0.3	33
75	Absence of mutations in the hypoxia response element ofVEGF in ALS. Muscle and Nerve, 2003, 28, 774-775.	1.0	32
76	A Mutation that Creates a Pseudoexon in SOD1 Causes Familial ALS. Annals of Human Genetics, 2009, 73, 652-657.	0.3	32
77	Mutation analysis of PFN1 in familial amyotrophic lateral sclerosis patients. Neurobiology of Aging, 2013, 34, 1311.e1-1311.e2.	1.5	31
78	The importance of theSMNgenes in the genetics of sporadic ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 436-440.	2.3	30
79	A Rare Motor Neuron Deleterious Missense Mutation in theDPYSL3(CRMP4) Gene is Associated with ALS. Human Mutation, 2013, 34, 953-960.	1.1	30
80	Survival of newly postmitotic motoneurons is transiently independent of exogenous trophic support. Journal of Neuroscience, 1995, 15, 3128-3137.	1.7	29
81	Genetic analysis of SIGMAR1 as a cause of familial ALS with dementia. European Journal of Human Genetics, 2013, 21, 237-239.	1.4	29
82	MACVIA-LR, Reference site of the European Innovation Partnership on Active and Healthy Ageing (EIP on) Tj ETQq0 0 0 rgBT /Overlock 10	1.2	29
83	Analysis of the UNC13A Gene as a Risk Factor for Sporadic Amyotrophic Lateral Sclerosis. Archives of Neurology, 2010, 67, 516-7.	4.9	28
84	Identification of novelFUSmutations in sporadic cases of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 113-117.	2.3	28
85	Liver X Receptor Genes Variants Modulate ALS Phenotype. Molecular Neurobiology, 2018, 55, 1959-1965.	1.9	28
86	Searching for a link between the L-BMAA neurotoxin and amyotrophic lateral sclerosis: a study protocol of the French BMAALS programme. BMJ Open, 2014, 4, e005528-e005528.	0.8	25
87	Strategy for anti-aquaporin-4 auto-antibody identification and quantification using a new cell-based assay. Clinical Immunology, 2011, 138, 239-246.	1.4	24
88	Motoneuron survival factors: Biological roles and therapeutic potential. Neuromuscular Disorders, 1993, 3, 455-458.	0.3	23
89	N19S, a new SOD1 mutation in sporadic amyotrophic lateral sclerosis: No evidence for disease causation. Annals of Neurology, 2003, 53, 815-818.	2.8	23
90	Embryonic rat motoneurons express a functional P-type voltage-dependent calcium channel. International Journal of Developmental Neuroscience, 1995, 13, 429-436.	0.7	22

#	Article	IF	Citations
91	C9orf72 Hexanucleotide Repeat Expansions as the Causative Mutation for Chromosome 9p21â€“Linked Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Archives of Neurology, 2012, 69, 1159-63.	4.9	22
92	Study of the HFE gene common polymorphisms in French patients with sporadic amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 2012, 317, 58-61.	0.3	22
93	Homozygous SMN2 deletion is a protective factor in the Swedish ALS population. European Journal of Human Genetics, 2012, 20, 588-591.	1.4	21
94	ALS and environment: Clues from spatial clustering?. Revue Neurologique, 2019, 175, 652-663.	0.6	21
95	An amyotrophic lateral sclerosis hot spot in the French Alps associated with genotoxic fungi. Journal of the Neurological Sciences, 2021, 427, 117558.	0.3	21
96	Motor evoked potentials (MEPs): evaluation of the different types of responses in amyotrophic lateral sclerosis and primary lateral sclerosis. Electromyography and Clinical Neurophysiology, 1996, 36, 361-8.	0.2	21
97	Genetic screening of ANXA11 revealed novel mutations linked to amyotrophic lateral sclerosis. Neurobiology of Aging, 2021, 99, 102.e11-102.e20.	1.5	20
98	Questioning on the role of D amino acid oxidase in familial amyotrophic lateral sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, E107; author reply E108.	3.3	19
99	Identification of a FUS splicing mutation in a large family with amyotrophic lateral sclerosis. Journal of Human Genetics, 2011, 56, 247-249.	1.1	19
100	Peripheral Myelin Protein 22 gene duplication with atypical presentations: A new example of the wide spectrum of Charcot-Marie-Tooth 1A disease. Neuromuscular Disorders, 2014, 24, 524-528.	0.3	18
101	CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy. Neurology, 2016, 87, 2491-2494.	1.5	18
102	APOE Îµ4 allele is associated with an increased risk of bulbar-onset amyotrophic lateral sclerosis in men. European Journal of Neurology, 2011, 18, 1046-1052.	1.7	17
103	High-risk syndrome for neuromyelitis optica: a descriptive and comparative study. Multiple Sclerosis Journal, 2011, 17, 720-724.	1.4	17
104	Adult-onset spinal muscular atrophy: An update. Revue Neurologique, 2017, 173, 308-319.	0.6	17
105	Exploring the diagnosis delay and ALS functional impairment at diagnosis as relevant criteria for clinical trial enrolment*. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 519-527.	1.1	17
106	Amyotrophic lateral sclerosis transcriptomics reveals immunological effects of low-dose interleukin-2. Brain Communications, 2021, 3, fcab141.	1.5	17
107	Neurotrophic factors in development and plasticity of spinal neurons. Restorative Neurology and Neuroscience, 1993, 5, 15-28.	0.4	16
108	Erythema nodosum and glatiramer acetate treatment in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2007, 13, 941-944.	1.4	16

#	Article	IF	Citations
109	SMN1 gene study in three families in which ALS and spinal muscular atrophy co-exist. Neurology, 2002, 59, 1464-1466.	1.5	14
110	Letter to the editor. Muscle and Nerve, 2000, 23, 1610-1611.	1.0	13
111	Oligogenicity, C9orf72 expansion, and variant severity in ALS. Neurogenetics, 2020, 21, 227-242.	0.7	13
112	High rate of hypomorphic variants as the cause of inherited ataxia and related diseases: study of a cohort of 366 families. Genetics in Medicine, 2021, 23, 2160-2170.	1.1	13
113	Purification of Spinal Motoneurons from Chicken and Rat Embryos by Immunopanning. Methods, 1993, 2, 191-199.	0.5	12
114	Cutaneous adverse events related to glatiramer acetate injection (copolymerâ€1,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 547 Td (Copaxo 2009, 23, 1332-1333.	1.3	12
115	Increased worsening of amyotrophic lateral sclerosis patients during Covid-19-related lockdown in France. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 505-507.	1.1	12
116	Liver X receptors: from cholesterol regulation to neuroprotectionâ€"a new barrier against neurodegeneration in amyotrophic lateral sclerosis?. Cellular and Molecular Life Sciences, 2016, 73, 3801-3808.	2.4	11
117	Mechanism of action of s1p receptor modulators in multiple sclerosis: The double requirement. Revue Neurologique, 2020, 176, 100-112.	0.6	11
118	The relationship between the rate of brain volume loss during first 24Âmonths and disability progression over 24 and 48Âmonths in relapsing MS. Journal of Neurology, 2016, 263, 299-305.	1.8	10
119	Teriflunomideâ€induced psoriasiform changes of fingernails: a new example of paradoxical side effect?. International Journal of Dermatology, 2017, 56, 1479-1481.	0.5	10
120	Clinical Phenotype and Inheritance in Patients With C9ORF72 Hexanucleotide Repeat Expansion: Results From a Large French Cohort. Frontiers in Neuroscience, 2020, 14, 316.	1.4	10
121	Coexistence of amyotrophic lateral sclerosis and Werdnig-Hoffmann disease within a family. Muscle and Nerve, 1993, 16, 569-70.	1.0	10
122	Association study of the ubiquitin conjugating enzyme gene UBE2H in sporadic ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 432-435.	2.3	9
123	Ipsilateral Uveitis and Optic Neuritis in Multiple Sclerosis. Multiple Sclerosis International, 2012, 2012, 1-4.	0.4	9
124	High-dose pharmaceutical grade biotin (MD1003) in amyotrophic lateral sclerosis: A pilot study. EClinicalMedicine, 2020, 19, 100254.	3.2	9
125	Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS) Tj ETQq1 1 0.784314 rgBT /Overlo 821-831.	4.9	9
126	KCC3 loss-of-function contributes to Andermann syndrome by inducing activity-dependent neuromuscular junction defects. Neurobiology of Disease, 2017, 106, 35-48.	2.1	8

#	Article	IF	Citations
127	Phenotypic and genotypic studies of ALS cases in ALS-SMA families. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 432-437.	1.1	8
128	Pre-symptomatic diagnosis in ALS. Revue Neurologique, 2020, 176, 166-169.	0.6	8
129	MACVIA-LR (FIGHTING CHRONIC DISEASES FOR ACTIVE AND HEALTHY AGEING IN LANGUEDOC-ROUSSILLON): A SUCCESS STORY OF THE EUROPEAN INNOVATION PARTNERSHIP ON ACTIVE AND HEALTHY AGEING. Journal of Frailty & Aging,the, 2016, 5, 1-9.	0.8	8
130	The P413L chromogranin B variation in French patients with sporadic amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 210-214.	2.3	7
131	Effect of familial clustering in the genetic screening of 235 French ALS families. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 479-484.	0.9	7
132	Impact of a frequent nearsplice SOD1 variant in amyotrophic lateral sclerosis: optimising SOD1 genetic screening for gene therapy opportunities. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 942-949.	0.9	7
133	SLITRK2, an X-linked modifier of the age at onset in C9orf72 frontotemporal lobar degeneration. Brain, 2021, 144, 2798-2811.	3.7	7
134	Repeated neurofilament light chain measurements did not capture Riluzole therapeutic effect in amyotrophic lateral sclerosis patients. CNS Neuroscience and Therapeutics, 2022, 28, 1532-1538.	1.9	7
135	Respiratory onset in an ALS family with L144F SOD1 mutation. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 747-749.	0.9	6
136	A common functional allele of the Nogo receptor gene, reticulon 4 receptor (RTN4R), is associated with sporadic amyotrophic lateral sclerosis in a French population. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 490-496.	1.1	6
137	Low 25OH Vitamin D Blood Levels Are Independently Associated With Higher Amyotrophic Lateral Sclerosis Severity Scores: Results From a Prospective Study. Frontiers in Neurology, 2020, 11, 363.	1.1	6
138	Patient satisfaction following transition from the original to the new formulation of subcutaneous interferon beta-1a in relapsing multiple sclerosis: a randomized, two-arm, open-label, Phase IIIb study. Patient Preference and Adherence, 2010, 4, 127.	0.8	4
139	The Use of Peripherally Inserted Central Catheter in Amyotrophic Lateral Sclerosis Patients at a Later Stage. European Neurology, 2017, 77, 87-90.	0.6	4
140	Aquaporin 4 distribution in the brain and its relevance for the radiological appearance of neuromyelitis optica spectrum disease. Journal of Neuroradiology, 2021, 48, 170-175.	0.6	4
141	Editorial: Vitamin D in Neurological Diseases: From Pathophysiology to Therapy. Frontiers in Neurology, 2021, 12, 614900.	1.1	4
142	Diabetes insipidus as a first manifestation in multiple sclerosis. Neurology, 2011, 76, 1939-1940.	1.5	3
143	Autosomal dominant SPG9: intrafamilial variability and onset during pregnancy. Neurological Sciences, 2020, 41, 1931-1933.	0.9	3
144	Evidence of mosaicism in SPAST variant carriers in four French families. European Journal of Human Genetics, 2021, 29, 1158-1163.	1.4	3

#	Article	IF	Citations
145	Long-Term Effectiveness, Safety and Tolerability of Fingolimod in Patients with Multiple Sclerosis in Real-World Treatment Settings in France: The VIRGILE Study. Neurology and Therapy, 2022, 11, 633-658.	1.4	3
146	Analysis of the SORT1 gene in familial amyotrophic lateral sclerosis. Neurobiology of Aging, 2012, 33, 1845.e7-1845.e9.	1.5	2
147	<scp>SOD</scp>1 mutation can mask C9<scp>orf</scp>72 abnormal expansion. European Journal of Neurology, 2017, 24, e24.	1.7	2
148	Slowly progressive motor neuron disease with multi-system involvement related to p.E121G SOD1 mutation. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 296-297.	1.1	1
149	Theme 4 In vivo experimental models. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 160-187.	1.1	1
150	NOMADâ€™ MUS : crÃ©ation dâ€™une cohorte franÃ§aise de neuro-optico-myÃ©lite aiguÃ« de Devic et des syndromes neurologiques apparentÃ©s. Revue Neurologique, 2009, 165, S57-S58.	0.6	0
151	NeuromyÃ©lite optique de Devic et patients Ã haut risquÃ© : enquÃªte rÃ©trospective nationale. Revue Neurologique, 2009, 165, S55-S56.	0.6	0
152	Subcutaneous IFN-Î²1a to treat relapsingâ€“remitting multiple sclerosis. Expert Review of Neurotherapeutics, 2012, 12, 1283-1291.	1.4	0
153	ConnaÃ®tre la sclÃ©rose latÃ©rale amyotrophique pour mieux accompagner lesÂpatients. Actualites Pharmaceutiques, 2020, 59, 22-25.	0.0	0
154	Prise enÂcharge dâ€™uneÂpersonne atteinte deÂsclÃ©rose latÃ©rale amyotrophique. Actualites Pharmaceutiques, 2020, 59, 26-28.	0.0	0